Trial Profile
A Phase Ib dose finding study of fruquintinib in combination with Taxotere® in gastric cancer.
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 21 Sep 2022
Price :
$35
*
At a glance
- Drugs Docetaxel (Primary) ; Fruquintinib (Primary)
- Indications Gastric cancer
- Focus Adverse reactions
- 27 Sep 2016 New trial record
- 02 Aug 2016 According to a Chi-Med media release, company is enrolling patients in this trial to expand the data-set.